Neoleukin Therapeutics Inc (NLTX) stock is up 613.30% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives NLTX stock a score of 85 out of a possible 100.
That rank is chiefly influenced by a short-term technical score of 99. NLTX's rank also includes a long-term technical score of 95. The fundamental score for NLTX is 60. In addition to the average rating from Wall Street analysts, NLTX stock has a mean target price of 22. This means analysts expect the stock to rise 32.37% over the next 12 months.
What's Happening with NLTX Stock Today
Neoleukin Therapeutics Inc (NLTX) stock is up 9.78% while the S&P 500 is up 0.59% as of 3:58 PM on Tuesday, Jun 30. NLTX is up $1.48 from the previous closing price of $15.14 on volume of 508,212 shares. Over the past year the S&P 500 has gained 3.60% while NLTX is up 613.30%. NLTX lost -$2.67 per share in the over the last 12 months.